Christophe Macri, Matthew Paxman, Devi Jenika, Xiao Peng Lin, Zahra Elahi, Paul A. Gleeson, Irina Caminschi, Mireille H. Lahoud, Jose A. Villadangos, Justine D. Mintern
{"title":"FcRn 调节 DEC205 靶向疫苗下游树突状细胞的抗原递呈","authors":"Christophe Macri, Matthew Paxman, Devi Jenika, Xiao Peng Lin, Zahra Elahi, Paul A. Gleeson, Irina Caminschi, Mireille H. Lahoud, Jose A. Villadangos, Justine D. Mintern","doi":"10.1038/s41541-024-00854-8","DOIUrl":null,"url":null,"abstract":"<p>Dendritic cell (DC)-targeted vaccination is a new mode of antigen delivery that relies on the use of monoclonal antibodies (mAb) to target antigen to specific DC subsets. The neonatal Fc receptor (FcRn) is a non-classical Fc receptor that binds to immunoglobulin G (IgG) in acidified endosomes and controls its intracellular transport and recycling. FcRn is known to participate in the antigen presentation of immune complexes, however its contribution to DC-targeted vaccination has not previously been examined. Here we have investigated the role of FcRn in antigen presentation using antigen conjugated to IgG mAb which target specific DC receptors, including DEC205 and Clec9A expressed by the conventional DC 1 (cDC1) subset. We show that FcRn is expressed at high levels by cDC1, both at steady-state and following activation and plays a significant role in MHC I cross-presentation and MHC II presentation of antigens that are targeted to cDC1 via mAb specific for DEC205. This effect of FcRn is intrinsic to cDC1 and FcRn impacts the efficacy of anti-DEC205-mediated vaccination against B cell lymphoma. In contrast, FcRn does not impact presentation of antigens targeted to Clec9A and does not regulate presentation of cell-associated antigen. These data highlight a new and unique role of FcRn in controlling the immunogenicity of anti-DEC205-based vaccination, with consequences for exploiting this pathway to improve DC-targeted vaccine outcomes.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines\",\"authors\":\"Christophe Macri, Matthew Paxman, Devi Jenika, Xiao Peng Lin, Zahra Elahi, Paul A. Gleeson, Irina Caminschi, Mireille H. Lahoud, Jose A. Villadangos, Justine D. Mintern\",\"doi\":\"10.1038/s41541-024-00854-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Dendritic cell (DC)-targeted vaccination is a new mode of antigen delivery that relies on the use of monoclonal antibodies (mAb) to target antigen to specific DC subsets. The neonatal Fc receptor (FcRn) is a non-classical Fc receptor that binds to immunoglobulin G (IgG) in acidified endosomes and controls its intracellular transport and recycling. FcRn is known to participate in the antigen presentation of immune complexes, however its contribution to DC-targeted vaccination has not previously been examined. Here we have investigated the role of FcRn in antigen presentation using antigen conjugated to IgG mAb which target specific DC receptors, including DEC205 and Clec9A expressed by the conventional DC 1 (cDC1) subset. We show that FcRn is expressed at high levels by cDC1, both at steady-state and following activation and plays a significant role in MHC I cross-presentation and MHC II presentation of antigens that are targeted to cDC1 via mAb specific for DEC205. This effect of FcRn is intrinsic to cDC1 and FcRn impacts the efficacy of anti-DEC205-mediated vaccination against B cell lymphoma. In contrast, FcRn does not impact presentation of antigens targeted to Clec9A and does not regulate presentation of cell-associated antigen. These data highlight a new and unique role of FcRn in controlling the immunogenicity of anti-DEC205-based vaccination, with consequences for exploiting this pathway to improve DC-targeted vaccine outcomes.</p>\",\"PeriodicalId\":19335,\"journal\":{\"name\":\"NPJ Vaccines\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41541-024-00854-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-00854-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
树突状细胞(DC)靶向疫苗接种是一种新的抗原递送模式,它依靠单克隆抗体(mAb)将抗原靶向特定的DC亚群。新生儿 Fc 受体(FcRn)是一种非典型 Fc 受体,能与酸化内体中的免疫球蛋白 G(IgG)结合,并控制其在细胞内的转运和循环。众所周知,FcRn 参与免疫复合物的抗原递呈,但它对直流电靶向疫苗接种的贡献以前还没有研究过。在这里,我们使用抗原与 IgG mAb 连接研究了 FcRn 在抗原递呈中的作用,IgG mAb 靶向特定的 DC 受体,包括传统 DC 1(cDC1)亚群表达的 DEC205 和 Clec9A。我们的研究表明,FcRn 在稳态和活化后都会在 cDC1 中高水平表达,并在 MHC I 交叉呈递和 MHC II 呈递抗原中发挥重要作用,这些抗原通过 DEC205 特异性 mAb 靶向 cDC1。FcRn 的这种作用是 cDC1 固有的,而且 FcRn 会影响抗 DEC205 介导的 B 细胞淋巴瘤疫苗接种的疗效。相反,FcRn 不会影响以 Clec9A 为靶标的抗原的递呈,也不会调节细胞相关抗原的递呈。这些数据突显了 FcRn 在控制基于抗 DEC205 疫苗接种的免疫原性方面的新的独特作用,对利用这一途径改善直流电靶向疫苗效果具有重要意义。
FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines
Dendritic cell (DC)-targeted vaccination is a new mode of antigen delivery that relies on the use of monoclonal antibodies (mAb) to target antigen to specific DC subsets. The neonatal Fc receptor (FcRn) is a non-classical Fc receptor that binds to immunoglobulin G (IgG) in acidified endosomes and controls its intracellular transport and recycling. FcRn is known to participate in the antigen presentation of immune complexes, however its contribution to DC-targeted vaccination has not previously been examined. Here we have investigated the role of FcRn in antigen presentation using antigen conjugated to IgG mAb which target specific DC receptors, including DEC205 and Clec9A expressed by the conventional DC 1 (cDC1) subset. We show that FcRn is expressed at high levels by cDC1, both at steady-state and following activation and plays a significant role in MHC I cross-presentation and MHC II presentation of antigens that are targeted to cDC1 via mAb specific for DEC205. This effect of FcRn is intrinsic to cDC1 and FcRn impacts the efficacy of anti-DEC205-mediated vaccination against B cell lymphoma. In contrast, FcRn does not impact presentation of antigens targeted to Clec9A and does not regulate presentation of cell-associated antigen. These data highlight a new and unique role of FcRn in controlling the immunogenicity of anti-DEC205-based vaccination, with consequences for exploiting this pathway to improve DC-targeted vaccine outcomes.
NPJ VaccinesImmunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍:
Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.